AstraZeneca Plc (NASDAQ:AZN) released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in combination with standard-of-care chemotherapy for advanced biliary tract cancer (BTC). The data showed that Imfinzi plus standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit in advanced biliary tract cancer patients at three years. The company says the TOPAZ-1 results are the longest survival follow-up ever reported for a global, randomized Phase 3 trial in this setting. Related: New Hope for Aggressive Lung Cancer: AstraZeneca’s Imfinzi Shows Promising Results in Phase 3 Trial. At more than three years (median follow-up of 41.3 months), results showed that Imfinzi plus chemotherapy reduced ...